Clinical characteristics of patients with BD divided according to the presence of serum anti-RLIP76 IgG immunoreactivity
| Characteristics . | Patients with serum anti-RLIP76 IgG, n = 11 . | Patients without serum anti-RLIP76 IgG, n = 26 . |
|---|---|---|
| Median age, y (range) | 33 (28-54) | 43.5 (27-58) |
| Sex, M/F | 8/3 | 19/7 |
| Median disease duration, y (range) | 4.8 (0-14) | 6 (0-24) |
| Median C-reactive protein, mg/L | 3.2 (3.2-15.2) | 4.4 (0-129) |
| (range) | ||
| Genital ulcerations, % | 45.4 | 38.5 |
| Skin lesions, % | 54.5 | 61.5 |
| Eye involvement, % | 54.5 | 69.2 |
| Vascular manifestations, % | 36.4 | 20.8 |
| Arthrites, % | 9 | 23.1 |
| HLA B51, % | 75 | 66.6 |
| Active disease, % | 45.4 | 42.3 |
| Characteristics . | Patients with serum anti-RLIP76 IgG, n = 11 . | Patients without serum anti-RLIP76 IgG, n = 26 . |
|---|---|---|
| Median age, y (range) | 33 (28-54) | 43.5 (27-58) |
| Sex, M/F | 8/3 | 19/7 |
| Median disease duration, y (range) | 4.8 (0-14) | 6 (0-24) |
| Median C-reactive protein, mg/L | 3.2 (3.2-15.2) | 4.4 (0-129) |
| (range) | ||
| Genital ulcerations, % | 45.4 | 38.5 |
| Skin lesions, % | 54.5 | 61.5 |
| Eye involvement, % | 54.5 | 69.2 |
| Vascular manifestations, % | 36.4 | 20.8 |
| Arthrites, % | 9 | 23.1 |
| HLA B51, % | 75 | 66.6 |
| Active disease, % | 45.4 | 42.3 |
P > .05 for all characteristics.